(IBB)

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on Febru...

IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar o...

The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fuelin...

As of the latest data available, the top three holdings in the iShares Biotechnology ETF (NASDAQ: IBB) are: These three companies collectively represent approximately 25.68% of the Biotechnology Secto...

Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks...